Ipsen and Institute de Cancerologie Gustave-Roussy partner in a three-year deal to identify new targets, drug candidates and biomarkers to treat cancer

Ipsen Group

France / Mid-Cap Biopharma ($1-$50 billion)

Other

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Institute de Cancerologie Gustave-Roussy

France / Academic

Other

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced